Sarepta Therapeutics | SRPT - 销售和管理费用



金融业
股票价格
USD
资产
USD 3.19B
现金及等价物
USD 571.15M
销售成本
USD 150.1M
流动资产
USD 2.22B
流动负债
USD 502.91M
债务
USD 1.04B
EBIT
USD 13.29M
EBITDA
USD 375.48M
员工
1.37K
EPS每股收益
USD 0.64
股本和储备
USD 1.53B
销售毛利
USD 251.15M
债务利息支出
USD 21.51M
利息收入
USD 7M
贷款资金
USD 847.62M
市值
USD 1.66B
净收入
USD 330.96M
营业费用
USD 387.96M
营业利润
USD 13.29M
普通股股本
USD 105.62M
PE价格收益
27.27
税前利润
USD -1.75M
销售收入
USD 401.3M
销售和管理费用
USD 107.6M
股票
USD 904.27M
贸易债权人
USD 50.98M
应收帐款人
USD 393.8M


销售和管理费用 更改 日
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Amgen USD 1.72B 134M 2026-06
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
Biogen USD 709.7M 155.4M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Capricor Therapeutics USD 1.92M 446.47K 2025-12
Daiichi Sankyo JPY 249.96B 21.73B 2026-06
Eli Lilly USD 3.43B 496M 2026-06
Gilead Sciences USD 1.52B 70M 2026-06
Incyte USD 351.73M 23.64M 2026-06
Insmed USD 247.47M 208K 2026-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Moderna USD 216M 43M 2026-06
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novavax USD 25.53M 1.34M 2025-12
Pfizer USD 3.41B 496M 2026-06
PTC Therapeutics USD 73.89M 13.31M 2026-03
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.63B 307M 2026-06
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Tectonic Therapeutic USD 6.43M 2.99M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06